Peptide therapy on TikTok: separating signal from hype

What did @steelhealthandhor actually say?

The creator was explaining how different peptides compare on half-life and their downstream effects on GH and IGF-1. They claimed that Sermorelin has a mild effect, Tesamorelin has a "much higher" effect, and CJC-1295 produces a "large and sustained" elevation, not by raising peak GH output but by raising troughs. That last point, the trough distinction, is actually the most interesting and substantive thing said here.

The transcript is incomplete and context-dependent, referencing a longer comparison that was apparently started earlier in the video. That makes a clean fact-check tricky. But the core pharmacological claim, that CJC-1295 works differently from shorter-acting secretagogues because it elevates baseline GH between pulses rather than amplifying peaks, is a real and well-documented distinction worth examining.

Does the science back this up?

Mostly, yes. The half-life hierarchy described is accurate. The mechanism explanation for CJC-1295 is also grounded in published data, though "troughs" is a simplified way to describe what's happening.

Sermorelin has a plasma half-life of roughly 10 to 20 minutes. It mimics a natural GH-releasing hormone pulse and is cleared quickly. Tesamorelin, a stabilized GHRH analog approved by the FDA for HIV-associated lipodystrophy, has a longer effective half-life and produces more robust GH stimulation. CJC-1295 with DAC (Drug Affinity Complex) binds albumin and has a half-life measured in days, around 6 to 8 days per Walker et al. (2006, Growth Hormone and IGF Research). That study showed CJC-1295 produced sustained increases in GH and IGF-1 over weeks with once-weekly dosing, with GH levels remaining elevated between doses rather than spiking and crashing.

The concept of "elevated troughs" is a reasonable lay description of what albumin binding does: it creates a slow-release depot effect that keeps GH levels persistently higher between pulses rather than generating sharper peaks.

What did they get wrong (or right)?

The creator got the directional pharmacology right. The trough elevation point is accurate and often overlooked in peptide discussions that fixate on peak GH numbers. Credit where it's due.

What's incomplete is the framing around IGF-1. The creator says CJC-1295 has a large effect on "IGF-1 elevation" which is true, but IGF-1 elevation driven by sustained GH exposure has a different clinical profile than acute GH pulses. Chronic IGF-1 elevation is not automatically better. Teichman et al. (2006, Journal of Clinical Endocrinology and Metabolism) found sustained GH increases with CJC-1295, but the clinical implications of prolonged IGF-1 elevation, particularly for metabolic and oncologic risk, were not the subject of that trial and remain poorly studied in healthy adults using these compounds.

The creator also uses the term "Serma-Rellen" which appears to be a pronunciation of Sermorelin, and "Tessa-Merellen" for Tesamorelin. No factual error there, just odd audio. More concerning is what's missing: any mention of the fact that CJC-1295 with DAC is not FDA-approved and its long-term safety in non-HIV, non-GH-deficient populations is essentially unknown.

What should you actually know?

The half-life ladder, Sermorelin shortest, Tesamorelin middle, CJC-1295 with DAC longest, is pharmacologically real. But longer half-life is not synonymous with better or safer. The sustained IGF-1 elevation that CJC-1295 produces is the mechanism people want for body composition and recovery goals. It is also the mechanism that makes long-term safety an open question.

Tesamorelin has FDA approval, clinical trial data, and an established safety record, but only for a specific indicated population. Sermorelin has a long history of clinical use in pediatric GH deficiency. CJC-1295 with DAC has one notable human pharmacokinetic study and limited follow-up data beyond that. Using it based on the pharmacology of approved drugs is a logical leap that the evidence does not fully support yet.

• CJC-1295 with DAC binds albumin, extending its half-life to approximately 6-8 days (Walker et al., 2006, Growth Hormone and IGF Research)
• Tesamorelin is FDA-approved only for HIV-associated lipodystrophy, not general GH optimization
• Sermorelin's short half-life closely mirrors natural GHRH pulses, which some researchers consider a safety feature
• Long-term IGF-1 elevation in healthy adults using GH secretagogues has not been studied in adequately powered trials